[Corrigendum] Rab22a is a novel prognostic marker for cell progression in breast cancer
Affiliations: Department of Anesthesia, The Second Hospital of Jilin University, Changchun, Jilin 130022, P.R. China, Department of General Surgery, Xi'an Central Hospital, Xi'an, Shanxi 710000, P.R. China, Department of Pathology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Breast Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
- Published online on: January 11, 2021 https://doi.org/10.3892/ijmm.2021.4851
- Article Number: 18
Copyright : © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Int J Mol Med 45: [Related article:] 1037-1046, 2020; DOI: 10.3892/ijmm.2020.4486
Following the publication of this article, the authors have realized that Table I contained an error: The number of patients who were alive in the Rab22a high expression group should have been written as 77 instead of 772.
Clinicopathological characteristics of patient samples and expression of Rab22a in breast cancer.
A corrected version of the Table is shown on the next page (the corrected datum is highlighted in bold). The authors sincerely apologize for the error that was introduced during the preparation of this Table, and regret any inconvenience that this mistake has caused.